Funds to Support Development and Commercial Launch of Next Generation Adaptive Vapor Ablation System, Study of Post-Ablation Cavity Access MENLO PARK, Calif., November 12, 2018-- AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, announced that it has raised $17 million in financing led by Solas BioVentures and its affiliates. The proceeds will be used to fund AEGEA’s prospective, multi center Post-Ablation Cavity Access (PACE II) study to evaluate uterine cavity access and the possibility of minimally invasive interventions three to four years following ablation treatment.